HALEOS LABS LIMITED Announces Financial Results, Dividend Recommendation, and Key Governance Updates

HALEOS LABS LIMITED Announces Financial Results, Dividend Recommendation, and Key Governance Updates​

HALEOS LABS LIMITED (formerly known as SMS Lifesciences India Limited) announced significant updates following its Board of Directors meeting held on May 29, 2026. The company approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and recommended a dividend payout.

The Board also addressed key changes in the company’s governance structure, including the resignation of an Independent Director and the reconstitution of key internal committees.

Financial Results for FY 2025-26​

The company confirmed that its statutory auditors, M/s Rambabu & Co., issued an unmodified audit report on the standalone and consolidated financial results for the year ended March 31, 2026.

The Board recommended a dividend of 1.501% (15%) per equity share of face value for the financial year 2025-26, pending approval from the shareholders at the ensuing Annual General Meeting.

The detailed financial performance for the Standalone entity (in Rs. Lakhs) is as follows:

Standalone Financial Results Highlights (Rs. Lakhs)


For the consolidated group (in Rs. Lakhs), the total revenue reached 33,622.79 for the year ended March 31, 2026.

Consolidated Financial Results Highlights (Rs. Lakhs)


The financial summaries provided by the company for the period ending March 31, 2026, include:

• Standalone Statement of Assets and Liabilities (in Rs. Lakhs)
• Standalone Statement of Cash Flow (in Rs. Lakhs)
• Consolidated Statement of Assets and Liabilities (in Rs. Lakhs)
• Consolidated Statement of Cash Flow (in Rs. Lakhs)

Governance and Board Changes​

Several key governance actions were passed by the Board of Directors:

1. Resignation of Director: Mrs. Sundaramma Patibandla resigned from the position of Independent Director, effective May 29, 2026.
2. Committee Reconstitution: The Board reconstituted the Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee to accommodate the change in directorship.
3. Director Reappointment: Mrs. Sudeepthi Gopineedi was reappointed as Whole-time Director for a further period of five consecutive years, effective September 2, 2026, subject to shareholder approval.
4. Remuneration Approval: The Board approved the overall Managerial Remuneration payable to Executive Director(s), subject to shareholder approval.

Audit and Audit Appointments​

The meeting included items pertaining to the appointment and reappointment of statutory and cost auditors.

• Statutory Auditors: The company proposed the appointment of M/s Suryanarayana & Suresh, Chartered Accountants (Firm Regt no. 0066315), as statutory Auditors for a period of five years, subject to shareholder approval.
• Cost Auditors: The company proposed the reappointment of M/s Annapragada & Co. (formerly known as "Harshitha Annapragada & Co."), Cost Accountants (FRN: 0060311), as Cost Auditors for the year 2026-27, subject to shareholder approval.

In addition, the company updated its key managerial personnel (KMP) contacts:


The company also confirmed that the consolidated financial results include the share of profit/loss of its subsidiary, Mahi Drugs Private Limited.

HALEOSLABS Stock Price Movement​

Shares of HALEOS LABS LIMITED today slipped by 4.58% to settle at ₹1581.3, concluding the trading day. The stock saw a total traded volume of 1,467 shares during the session.